Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pinpointing navacaprant trial costs, cash runway, or when Neumora’s executives sell shares shouldn’t demand hours with dense biotech prose. Yet Neumora Therapeutics’ neuroscience focus means every 8-K safety update, 10-Q R&D footnote, and Form 4 insider trade carries weight for valuation. If you’ve ever typed “Neumora Therapeutics SEC filings explained simply” and still felt lost, this page is built for you.
Stock Titan’s AI breaks down complexity. Our models surface what matters in the exact filing you need: the “Neumora Therapeutics quarterly earnings report 10-Q filing” is summarised into cash burn, trial milestones, and partnership revenue in seconds; “Neumora Therapeutics insider trading Form 4 transactions” trigger real-time alerts, while “Neumora Therapeutics 8-K material events explained” highlights pipeline pauses or fast-track designations. No jargon, just direct answers—perfect for understanding Neumora Therapeutics SEC documents with AI.
Here’s where each form delivers insight:
- 10-K: See risk factors, segment spend, and have the Neumora Therapeutics annual report 10-K simplified for quick reading.
- 10-Q: Track quarter-over-quarter R&D shifts with Neumora Therapeutics earnings report filing analysis.
- Form 4: Follow Neumora Therapeutics executive stock transactions Form 4 and Form 4 insider transactions real-time.
- DEF 14A: Review the Neumora Therapeutics proxy statement executive compensation details without hunting through exhibits.
- 8-K: Immediate context when trials advance or partnerships form.
With comprehensive coverage, AI-powered summaries, and continuous EDGAR feeds, you can finally connect clinical progress to financial impact—faster than scrolling through 300-page PDFs.
Neumora Therapeutics reported a Q3 2025 net loss of $56.8 million, with nine‑month net loss at $177.5 million. Operating expenses fell year over year as research and development declined to $40.5 million from $60.6 million, and general and administrative to $12.2 million from $16.0 million. The company recorded $5.0 million of acquired in‑process R&D tied to its Vanderbilt M4 program.
Cash, cash equivalents and marketable securities totaled $171.5 million as of September 30, 2025. Neumora believes this will fund operations for at least the next 12 months. In May, it drew $20.0 million from a term loan facility with K2 HealthVentures (up to $125.0 million across tranches) at a minimum rate of 10.45%, and subsequently borrowed an additional $40.0 million after quarter‑end.
The pipeline includes a Phase 3 program for navacaprant in major depressive disorder and a Phase 1b study for NMRA‑511 in agitation due to Alzheimer’s disease, with early‑stage M4 PAM candidates advancing. Shares outstanding were 167,089,114 as of November 1, 2025.
Neumora Therapeutics, Inc. furnished an 8-K stating it announced financial results for the second quarter ended September 30, 2025. The full details are provided in a press release attached as Exhibit 99.1.
The company notes that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. The report was signed by Chief Financial Officer Michael Milligan on November 6, 2025.
Neumora Therapeutics (NMRA)1,915,700 shares of common stock at $2.61 on 10/27/2025, recorded as an indirect transaction by ARCH Venture Fund XII, L.P.
Following the transaction, reported beneficial holdings include: 6,046,907 shares indirectly via ARCH Venture Fund XII, L.P.; 1,387,228 via ARCH Venture Fund VII, L.P.; 2,321,566 via ARCH Venture Fund VIII Overage, L.P.; 12,205,379 via ARCH Venture Fund X, L.P.; 11,886,758 via ARCH Venture Fund X Overage, L.P.; and 47,717 shares held directly.
Neumora Therapeutics (NMRA) insider filing reports an open-market purchase by affiliated ARCH Venture funds. On 10/27/2025, the reporting persons acquired 1,915,700 shares of common stock at $2.61 per share, reported as indirectly owned.
Following the transaction, indirect beneficial holdings were listed as: 6,046,907 shares by ARCH Venture Fund XII, L.P.; 1,387,228 by ARCH Venture Fund VII, L.P.; 2,321,566 by ARCH Venture Fund VIII Overage, L.P.; 12,205,379 by ARCH Venture Fund X, L.P.; and 11,886,758 by ARCH Venture Fund X Overage, L.P. The filing is a joint submission, and a director relationship is indicated.
Neumora Therapeutics (NMRA): ARCH-affiliated reporting persons disclosed an insider purchase. On 10/27/2025, ARCH Venture Fund XII, L.P. bought 1,915,700 shares of common stock at $2.61 per share (Transaction Code P), reported as indirect ownership.
After the transaction, beneficial holdings reported include: 6,046,907 (ARCH XII); 12,205,379 (ARCH Venture Fund X, L.P.); 11,886,758 (ARCH Venture Fund X Overage, L.P.); 2,321,566 (ARCH Venture Fund VIII Overage, L.P.); and 1,387,228 (ARCH Venture Fund VII, L.P.). The filing was made jointly by multiple ARCH entities and certain individuals, with the relationship indicated as Director.
Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.
This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.
Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to
A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.
Neumora Therapeutics disclosed that K2 HealthVentures Equity Trust LLC and two managing members, Parag Shah and Anup Arora, report beneficial ownership tied to convertible debt that can be converted into Common Stock. Under a loan and security agreement, K2HV Equity has the right to convert up to $10,000,000 of principal into Conversion Shares at the lesser of $0.8774 per share or the lowest effective price in the Issuer's next equity financing; the filers assumed the $0.8774 conversion price.
As a result, the Reporting Persons disclose beneficial ownership of 11,397,310 shares, representing approximately 6.6% of Common Stock on a converted basis. The Schedule shows shared voting and dispositive power over those shares (no sole voting or dispositive power). The reporting address for the filers is provided as 855 Boylston Street, Boston, MA.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
